Drug intelligence / Profile preview

Loycoral

Development stage: Unknown
Lead developer: Lloyd Healthcare
Modality: Small Molecules
Administration: Oral

Overview

**Loycoral** is a Lloyd Healthcare oral calcium-replacement product containing 225 mg elemental calcium per unit. It is marketed in Lloyd Healthcare's orthopedic portfolio for prevention and treatment of calcium deficiency and support of bone health. The publicly available product listings do not identify the underlying calcium salt, so Loycoral should not be equated with a specific calcium salt formulation such as calcium carbonate or calcium citrate.

Brand names: Loycoral

Beyond the preview

Go deeper on Loycoral.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Loycoral.

Explore the full profile